Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting xience V stents in the randomized TWENTE trial: Comparison of 2-year clinical outcome

Hanim Sen, Ming Kai Lam, Kenneth Tandjung, Marije M. Löwik, Martin G. Stoel, Frits H.A.F. de Man, J. (Hans) W. Louwerenburg, Gert K. van Houwelingen, Gerard C.M. Linssen, Carine J.M. Doggen, Mounir W.Z. Basalus, Clemens von Birgelen

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)

Abstract

Objective: To assess the differences in clinical outcome between complex patients treated with Resolute zotarolimus-eluting stents (ZES) versus Xience V everolimus-eluting stents (EES).

Background: Nowadays, many complex patients with coronary disease are treated with percutaneous coronary interventions, using drug-eluting stents (DES).

Methods: We analyzed 2-year outcome data of 1,033 complex patients of the TWENTE trial, treated with second-generation Resolute ZES or Xience V EES. Complex patients had at least one of the following characteristics: renal insufficiency (creatinine ≥ 140 µmol/l); ejection fraction < 30%; acute myocardial infarction (MI) within previous 72 hrs; >1 lesion/vessel; >2 vessels treated; lesion length > 27 mm; bifurcation; saphenous vein graft lesion; arterial bypass graft lesion; in-stent restenosis; unprotected left main lesion; lesion with thrombus; or lesion with total occlusion. Target vessel failure (TVF), the primary composite endpoint of the trial, was defined as cardiac death, target vessel-related MI, or target vessel revascularization.

Results: Among the 1,033 complex patients, 529 (51%) were treated with Resolute ZES and 504 (49%) with Xience V EES. Patient- and procedure-related characteristics were similar between DES groups. After 2-year follow-up, outcome was also similar between DES groups. TVF occurred in 12.1% of patients treated with Resolute ZES and 12.3% of patients treated with Xience V EES. In addition, DES groups did not differ significantly in cardiac death, MI, or target vessel revascularization—the individual components of TVF.

Conclusion: Complex patients treated with Resolute ZES and Xience V EES showed similar safety and efficacy during 2-year follow-up.

Original languageEnglish
Pages (from-to)74-81
JournalCatheterization and cardiovascular interventions
Volume85
Issue number1
DOIs
Publication statusPublished - 14 Mar 2015

Keywords

  • METIS-304661
  • IR-91536
  • Drug-eluting stent(s)
  • Percutaneous Coronary Intervention (PCI)
  • TWENTE trial
  • Off-label

Fingerprint Dive into the research topics of 'Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting xience V stents in the randomized TWENTE trial: Comparison of 2-year clinical outcome'. Together they form a unique fingerprint.

Cite this